Good news for cancer treatment

WOMEN who have been taking tamoxifen while recovering from breast cancer can lower their chance of developing another tumour by switching to a new drug, exemestane, after two or three years of treatment.

According to preliminary results released yesterday by the New England Journal of Medicine, the Pfizer-financed study also found the switch to the Pfizer drug seemed to lower the risk of other types of cancers, too.

Tamoxifen is sold under the brand name Nolvadex by AstraZeneca, and is usually taken for five years.

more courts articles

Eva Green film project became ‘Shakespearean farce’, UK High Court told

Eva Green says it was ‘humiliating’ to have her WhatsApp messages read in court

Man arrested over murder of Natalie McNally

More in this section

Pakistan’s former military ruler Pervez Musharraf dies aged 79

China threatens ‘further actions’ after US shoots down suspected spying balloon

Witness comes forward in Nicola Bulley case as UK police warn against speculation

CourtsHealthOrganisation: New England Journal of MedicineOrganisation: PfizerOrganisation: AstraZeneca



Pope makes final bid for peace and forgiveness in South Sudan

READ NOW